An observational study in Post-Acute COVID-19 Syndrome, sponsored by A.T. Still University of Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-30.
Sponsored by A.T. Still University of Health Sciences · Observational
Among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 84 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.
Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 35th largest by enrollment of the 37 observational ones that give a count, is one of 53 that started in 2023, is one of 37 observational ones, and was the 99th registered.
604 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →63 of the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Stephanie B. Seminara, MD · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 146 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (36%) stop at 75 or younger; 15 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 53 · Phase 3 13 · Phase 4 4
First in 2020; this study’s year is marked. 53 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 52 across the 155 interventional studies, 155 across the 37 observational. Of the 96 that completed or were terminated, 30 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 194 have an industry lead sponsor. The 10 most frequent:
A.T. Still University of Health Sciences is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
A.T. Still University of Health Sciences has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
29 of the studies in Post-Acute COVID-19 Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06974084Phase 3HealthBio, Inc.A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | 2026-12-01 |
| NCT06960928Phase 3Icahn School of Medicine at Mount SinaiLow Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 | 2026-12-31 |
| NCT06511063Icahn School of Medicine at Mount SinaiAntiviral Clinical Trial for Long Covid-19 | 2026-11 |
Add all 29 to your calendar (.ics) → With an account.
Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to determine the feasibility of conducting a large-scale study on the effect of using osteopathic manipulative treatment (OMT) to treat patients with post-COVID-19 symptoms. The main questions it aims to answer are:
Participants will receive OMT as directed by their physician and complete questionnaires after every other OMT session.
Patients of clinics in the United States where members of the practice-based research network, DO-Touch.NET, practice osteopathic manipulative treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Osteopathic manipulative treatment provided at the discretion of the treating physician and based on the patient's response to previous treatments.
Patient recruitment rate (feasibility)
Proportion of patients who enroll in the study out of the number of patients who were eligible for and invited to enroll in the study.
Time frame: Through study completion, an average of 1 year
Data completion rate (feasibility)
Proportions of participants and physicians who complete all their questionnaires.
Time frame: Through study completion, an average of 1 year
Neurocognitive and psychological symptoms
Measured using the Rivermead Post Concussion Symptoms Questionnaire
Time frame: 3 days after every other OMT session for up to 4 months after enrollment and 2 months after the participant's final OMT session
Physical symptoms
Measured using the Long COVID-Household Pulse Survey
Time frame: 3 days after every other OMT session for up to 4 months after enrollment and 2 months after the participant's final OMT session
Global health
Measured using the PROMIS SF v1.2 Global Health scale
Time frame: 3 days after every other OMT session for up to 4 months after enrollment and 2 months after the participant's final OMT session
Return to work
For participants who were employed prior to COVID-19, their current working status will be assessed on a 4-point scale (1. returned to full-time work without restrictions, 2. returned to full-time work but with modified job duties, 3) returned to work but with reduced working hours, 4. have not been able to return to work.
Time frame: 3 days after every other OMT session for up to 4 months after enrollment and 2 months after the participant's final OMT session
Severity of potential adverse events from OMT
Measured by comparing the severity of potential adverse events from OMT during the 3 days following OMT to the severity during the week before OMT.
Time frame: 3 days after every other OMT session for up to 4 months after enrollment
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Jul 2024, 9 months.
Of 98 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 9 months is below that.
Counting every sponsor, half of 105 studies reached it within 27 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
A.T. Still University of Health Sciences